There were very few 3-point MACE events in the SUSTAIN/ASSURE trials as I've posted here and here. You can't just apply the 60% 3-point MACE event observation from one study to another study. And where are you getting a 77% RRR rosuvastatin and 50+% RRR all statin RRR? There was an ~77% RRR observed in diabetic patients and ~50% RRR observed in all patients in the ASSURE/SUSTAIN post-hocs. Is that what you mean? Again, you can't just apply and assume that 60% of 5-point MACE events are 3-point MACE events. Similarly, you can't assume that 60% of 5-point MACE in Amarin's REDUCE it are going to be 3-point MACE. We'll have to wait for AHA in a few weeks for that full data. Lastly, not all type of MACE events occur uniformly. One could see effect on heart attack and stroke but not on CVD death. So the RRR for each individual component of the 3-point or 5-point MACE may be different. Lastly, one could theoretically have the same RRR value for a 5-point MACE and 3-point MACE metric if all individual events are being reduced by the same amount. So applying a 60% correction to the 5-point MACE RRR to get a 3-point MACE RRR makes absolutely no sense.

BDAZ